Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study (CoachMS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03335618|
Recruitment Status : Completed
First Posted : November 8, 2017
Last Update Posted : August 20, 2020
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Other: Activity Monitoring and Symptom Coaching Other: Passive Activity Monitoring||Not Applicable|
MS is a chronic, debilitating disease of the central nervous system affecting approximately 2 million people worldwide and more than 400,000 individuals in the US. MS is the most common cause of non-traumatic neurological disability in young adults. Symptoms typically first afflict individuals during the prime of their professional and reproductive lives, between the ages of 20 and 40. Many affected individuals are unemployed, physically disabled, and at high risk for social isolation. While disease-modifying therapies (DMTs) can significantly reduce accumulation of disability in MS, patients still experience symptoms across a range of functional domains. Symptoms can include problems with bladder, walking, and mood (depression and anxiety). Often, these symptoms are only partially evaluated during routine MS clinic visits, and the long interval between clinic visits can result in them not being optimally managed.
The goal of the current study is to pilot a system of proactively monitoring a combination of symptoms (bladder, ambulation and mood) using an activity monitor and a smartphone.
Adult patients with MS who are experiencing symptoms in at least 2 of the 3 domains (bladder, ambulation, mood) will be enrolled. Visits will be at baseline (can be same day as routine visit to the MS clinic), and 3 months. Short surveys (<3 minutes to complete) will occur weekly, and longer surveys will occur at baseline, 6 weeks and 3 months. FitBit activity monitors will be worn for the entire 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||A First-in-Kind Randomized, Controlled Pilot Clinical Trial Testing Proactive vs Reactive Management of a Symptom Triad in Multiple Sclerosis|
|Actual Study Start Date :||October 1, 2017|
|Actual Primary Completion Date :||August 1, 2019|
|Actual Study Completion Date :||March 23, 2020|
|Experimental: Active Coaching and Monitoring||
Other: Activity Monitoring and Symptom Coaching
Triggered check-ins by study personnel to keep participants on track to meet fitness goals
|Sham Comparator: Passive Monitoring||
Other: Passive Activity Monitoring
Passive step tracking without check-ins
- Feasibility of an active symptom monitoring and intervention protocol [ Time Frame: 12 weeks ]To evaluate feasibility of the intervention, we will calculate how many patients remain in the study, levels of patient satisfaction with the monitoring and intervention, and we will analyze patient and provider feedback.
- Improvement in ambulation symptoms in MS participants [ Time Frame: 12 weeks ]Change in average daily step count according to FitBit step tracking. We will assess the mean observed change of daily steps between both the actively monitored group and the passively monitored group.
- Improvement in mood symptoms in MS participants. [ Time Frame: 12 weeks ]We will measure changes in the Center of Epidemiologic Studies Depression Scale-Revised (CES-D-R), which is a patient questionnaire that provides a measure of depression. It consists of 20 questions, each of which receives a score between 0 and 3, with higher scores indicating worse depression. The total CESD-R score (0-60) also permits categorization of no, mild, moderate and severe depression.
- Improvement in bladder symptoms in MS participants. [ Time Frame: 12 weeks ]At the end of the study, we will measure change in the Actionable Bladder Symptom Screening Tool (ABSST), which is a patient-reported scale that identifies patients who could benefit from lower urinary tract assessment and/or possibly treatment. It consists of 8 questions, each graded on 4 points, with higher scores indicating worse bladder function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03335618
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94158|
|Principal Investigator:||Riley M Bove, MD||University of California, San Francisco|